Results 241 to 250 of about 2,359,169 (353)

Patient Selection for Deep Brain Stimulation for Pantothenate Kinase-Associated Neurodegeneration. [PDF]

Tremor Other Hyperkinet Mov (N Y)
Chan JL, Rawls AE, Wong JK, Hogarth P, Hilliard JD, Okun MS.   +5 more
europepmc   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Selection and management of ventricular assist device patients: the Muenster experience

, 2000
Mario C. Deng, Michael Weyand, Dieter Hammel, Christopher H. Schmid, Sebastian Kerber, C. G. Schmidt, Günter Breithardt, Hans H. Scheld   +7 more
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Application and Validation of a transRADial Access Score (RAD-Access) in Patient Selection for Safe Radial Access in Liver Cancer Intra-Arterial Procedures. [PDF]

Cancers (Basel)
Iezzi R, Posa A, Contegiacomo A, Maresca A, Rodolfino E, Merlino B, Bilhim T, Guimaraes M.   +7 more
europepmc   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Patient selection and early withdrawal of life support in extracorporeal cardiopulmonary resuscitation (ECPR): Do we have a problem? [PDF]

Resusc Plus
Argudo E, Martínez-Martínez M, Vidal-Burdeus M, Torrella P, Riera J.   +4 more
europepmc   +1 more source

Patients' Perspectives of Factors Affecting Modality Selection: A National Kidney Foundation Patient Survey

, 2000
Karren King
openalex   +1 more source

Beyond digital twins: the role of foundation models in enhancing the interpretability of multiomics modalities in precision medicine

FEBS Open Bio, EarlyView.
This review highlights how foundation models enhance predictive healthcare by integrating advanced digital twin modeling with multiomics and biomedical data. This approach supports disease management, risk assessment, and personalized medicine, with the goal of optimizing health outcomes through adaptive, interpretable digital simulations, accessible ...
Sakhaa Alsaedi, Xin Gao, Takashi Gojobori   +2 more
wiley   +1 more source

Optimizing immunotherapy for lung cancer: integrating genetic alterations and the tumor mutational burden to refine patient selection. [PDF]

Transl Cancer Res
Sugawara T, Hakozaki T, Seike M, Hosomi Y.   +3 more
europepmc   +1 more source